T Cell Banking · Founding Cohort 2026

Bank your T cells today.
Keep your options open for life.

Your immune system is strongest before illness, treatment, or age can affect it. Incellix gives you a way to preserve that strength, so it’s there if you ever need them.

Reserve My Spot See how it works

No commitment required · Limited founding cohort places available

85%
Viability post-thaw
15yr
Proven storage window
GMP
Certified processing
3hr
Collection procedure
TCR CD8 PD-1 CD4 T LYMPHOCYTE
GMP-Certified Partner Facilities
PhD-Led Scientific Team
Cryogenic Storage at −196°C
Validated Long-Term Viability
Full Chain-of-Custody
The Clinical Reality

The T cells you have today
are the best you will ever have.

Chemotherapy, aging and chronic disease cause progressive T cell exhaustion, a biologically irreversible state. By the time many patients qualify for CAR-T therapy, their immune cells no longer meet the quality threshold required to manufacture an effective treatment. CAR-T therapy eligibility depends directly on the T cells you have at collection

~30%
of eligible patients cannot receive CAR-T therapy due to poor T cell quality after prior treatment lines
$35B
projected CAR-T therapy market by 2032 dependent entirely on T cell quality.
T cell exhaustion is irreversible.
Once exhausted, T cells cannot be restored — not by checkpoint inhibitors, not by any current therapy. Research in Science (Pauken et al., 2016) confirms exhaustion is locked in at the epigenetic level. Prevention is the only viable strategy.
The Process

Five steps. Fully managed.

1 · Reserve your spot
Join the waitlist. No payment, no commitment.
2 · Consultation
A 20-minute remote review confirms eligibility.
3 · Collection
A 3-hour outpatient leukapheresis at a certified partner center.
4 · Processing
Cells are isolated, validated, and cryopreserved. You receive a quality report.
5 · Long-term banking
Stored under full chain-of-custody. Incellix manages everything.
Who Incellix Is For

Act before you need to.

Genetic Risk Carriers
BRCA1, BRCA2, PALB2, Lynch syndrome. You know your risk before disease begins.
Most proactive
Pre-Treatment Patients
Recently diagnosed. Bank before chemotherapy begins — the window is short.
Highest urgency
Proactive Adults · 35–60
Biological insurance. Preserve cells at peak health, while you still can.
Long-term protection
Oncologists & Clinicians
Refer patients who could benefit. Ask about our clinical partnership program.
Referral partners
The Science Behind It

Two decades of
peer-reviewed immunology.

All claims on this page reflect published peer-reviewed research. Incellix does not conduct clinical research or develop proprietary protocols. We share the evidence so you can decide for yourself.

Cryopreservation preserves T cell viability long-term.

A 2025 Scientific Reports study confirmed that cryopreserved leukapheresis products retain functional T cell composition and viability comparable to fresh samples. Optimized protocols routinely retain over 85% viability after long-term storage at −196°C.
Gao et al., Scientific Reports 2025

Apheresis quality predicts CAR-T outcomes.

A landmark Nature Medicine study found that the proportion of naive and early memory T cells at apheresis is among the strongest predictors of CAR-T remission. Patients with less exhausted T cells had significantly better outcomes.
Fraietta et al., Nature Medicine 2018

T cell exhaustion is locked in at the epigenetic level.

Research in Science showed exhausted T cells undergo stable epigenetic reprogramming that persists even after antigen removal. This molecular lock cannot be reversed by any current therapy. Prevention is the only viable strategy.
Pauken et al., Science 2016

The molecular biology of T cell exhaustion.

The foundational paper by E. John Wherry in Nature Immunology defined T cell exhaustion as a distinct state — separate from memory or senescence — marked by progressive loss of effector function and sustained PD-1, TIM-3, LAG-3 expression.
Wherry, Nature Immunology 2011
Frequently Asked Questions

Everything you need to know
before you decide.

T cell banking is the proactive collection and long-term cryopreservation of your own T lymphocytes — your immune system's adaptive responders — at peak health, for potential future therapeutic use. Collection is performed via leukapheresis at a certified medical center; storage occurs at accredited biobanking facilities. Unlike cord blood banking (captured at birth), T cell banking is a service adults can use to preserve immune cells before age, illness, or treatment changes them.
No. T cell banking is a preservation service, not a medical treatment. Incellix does not provide diagnosis, therapy, or clinical management. The collection procedure is performed by certified medical professionals at partner facilities. Incellix coordinates the process and serves as your single point of contact.
Leukapheresis — the collection procedure — is performed at certified apheresis centers by trained medical staff. Cryopreservation and long-term storage occur at accredited biobanking facilities operating under validated protocols (GMP, FACT-JACIE, or equivalent). Incellix coordinates the partner network and ensures full chain-of-custody tracking from collection through long-term storage.
Research in Nature Medicine (Fraietta et al., 2018) showed T cell quality at the time of apheresis is one of the strongest predictors of CAR-T therapy outcomes. Chemotherapy and radiation cause progressive, often irreversible damage to T cells. Banking before treatment preserves cells in their highest-functioning state.

Fraietta et al., Nature Medicine 2018
T cell exhaustion is a distinct biological state caused by repeated antigen stimulation, chemotherapy, or chronic inflammation, marked by progressive loss of cytotoxic function. Research in Science (Pauken et al., 2016) confirmed exhaustion involves stable epigenetic reprogramming and cannot be reversed by checkpoint inhibitors or any current treatment. Prevention through proactive banking is the only viable strategy.

Pauken et al., Science 2016
T cell banking is most relevant for genetic risk carriers (BRCA1, BRCA2, PALB2, Lynch syndrome), pre-treatment cancer patients before chemotherapy or radiation, and proactive adults aged 35 to 60. Oncologists and clinicians can engage Incellix through a separate clinical referral pathway.
Incellix is in the founding cohort phase, building partnerships across Switzerland, Germany, and Italy. Joining the waitlist secures your priority position and signals demand in your region — directly influencing rollout sequencing. Founding cohort pricing will be shared with waitlist members ahead of launch. Joining involves no payment and no commitment.
Your cells are stored at independent, accredited third-party biobanking facilities — not at Incellix. In any scenario affecting Incellix's operations, your cells remain in the legal custody of those facilities. Transfer protocols and continuity provisions are part of every storage agreement.
Reserve Your Spot · Founding Cohort

Be among the first to
bank your immune future.

Register your interest below. We'll contact you when collection becomes available in your area. Founding members get priority access and preferred onboarding terms.

No payment required
Your data is never sold
Unsubscribe anytime

Any questions? Please contact us at: contactincellix@gmail.com · Privacy Policy

You're on the list.
Thank you for registering your interest.
Please check your inbox and confirm your email to complete your registration — look for a message from Incellix.

Incellix — banking the future of your immune system.